Real-world evidence on first-line treatment for metastatic renal cell carcinoma with non-clear cell and sarcomatoid histologies: are sunitinib and pazopanib interchangeable?

Imagem de Miniatura
Arquivos
art_BONADIO_Realworld_evidence_on_firstline_treatment_for_metastatic_renal_2019.PDF (663.76 KB)
Citações na Scopus
2
Tipo de produção
article
Data de publicação
2019
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
CANCER INTELLIGENCE LTD
Autores
Citação
ECANCERMEDICALSCIENCE, v.13, article ID 973, 12p, 2019
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Introduction: Non-clear cell renal cell carcinoma (nccRCC) and sarcomatoid renal cell carcinoma (sRCC) are underrepresented in clinical trials. Treatment approaches are frequently extrapolated from data of clear cell renal cell carcinoma, in which pazopanib is non-inferior to sunitinib. We aim to compare the effectiveness of first-line sunitinib and pazopanib for nccRCC and sRCC. Methods: We evaluated a retrospective cohort of patients with metastatic nccRCC and sRCC treated with first-line sunitinib or pazopanib at an academic cancer centre. Overall survival (OS), progression-free survival (PFS) and response rate were measured. Kaplan-Meier and log-rank analyses were used for time-to-event data. Cox regression was used for prognostic factors. Results: Fifty-three patients were included; 16 (30.1%) treated with sunitinib and 37 (69.9%) with pazopanib. Forty-six (86.8%) patients had nccRCC and 7 (13.2%) had sRCC. The majority had intermediate or poor International Metastatic Renal-Cell Carcinoma Database Consortium risk (93%). Median PFS was 6.6 months with sunitinib and 4.9 months with pazopanib (HR 1.75; P = 0.078). Treatment with pazopanib was associated with inferior OS in comparison with sunitinib (median OS: 30.4 months versus 8.7 months; HR 2.71, 95% CI 1.31-5.58, P = 0.007). These results were confirmed in subgroup analysis of patients with papillary, chromophobe and MiT family translocation histologies (median OS: 38.7 months versus 14.7 months; HR 3.16, 95% CI 1.20-8.29, P = 0.019). Unclassified and sarcomatoid histologies had inferior OS (median: 6.9 and 1.1 months, respectively) regardless of the treatment used. Conclusion: In this patient cohort, pazopanib was associated with inferior OS in comparison with sunitinib for metastatic nccRCC. Larger trials are ideally warranted to confirm these results.
Palavras-chave
non-clear cell, sarcomatoid, renal cell carcinoma, sunitinib, pazopanib
URI
https://observatorio.fm.usp.br/handle/OPI/34610
Referências
  1. Armstrong AJ, 2016, LANCET ONCOL, V17, P378, DOI 10.1016/S1470-2045(15)00515-X
  2. Beuselinck B, 2014, CLIN GENITOURIN CANC, V12, pE205, DOI 10.1016/j.clgc.2014.04.004
  3. Buti S, 2017, CLIN GENITOURIN CANC, V15, pE609, DOI 10.1016/j.clgc.2016.12.024
  4. Cheville JC, 2004, AM J SURG PATHOL, V28, P435, DOI 10.1097/00000478-200404000-00002
  5. Cohen HT, 2005, NEW ENGL J MED, V353, P2477, DOI 10.1056/NEJMra043172
  6. Durinck S, 2015, NAT GENET, V47, P13, DOI 10.1038/ng.3146
  7. Dutcher JP, 2009, MED ONCOL, V26, P202, DOI 10.1007/s12032-009-9177-0
  8. Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026
  9. El Mouallem N, 2018, UROL ONCOL-SEMIN ORI, V36, P265, DOI 10.1016/j.urolonc.2017.12.012
  10. Escudier B, RENAL CELL CARCINOMA
  11. Escudier B, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.4511
  12. Fernandez-Pello S, 2017, EUR UROL, V71, P426, DOI 10.1016/j.eururo.2016.11.020
  13. Heng DYC, 2013, LANCET ONCOL, V14, P141, DOI 10.1016/S1470-2045(12)70559-4
  14. Hsieh JJ, 2017, NAT REV DIS PRIMERS, V3, DOI [10.1038/nrdp.2017.10, 10.1038/nrdp.2017.9]
  15. Hudes G, 2007, NEW ENGL J MED, V356, P2271, DOI 10.1056/NEJMoa066838
  16. Jung KS, 2018, CANCER RES TREAT, V50, P488, DOI 10.4143/crt.2016.584
  17. Kotecha RR, 2019, NAT REV CLIN ONCOL, V1
  18. Linehan WM, 2016, NEW ENGL J MED, V374, P135, DOI 10.1056/NEJMoa1505917
  19. McDermott D, 2018, 17 INT KIDN CANC S
  20. McDermott DF, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.7_suppl.546
  21. MCKAY RR, 2019, J CLIN ONCOL S, V37
  22. Motzer RJ, 2018, NEW ENGL J MED, V378, P1277, DOI 10.1056/NEJMoa1712126
  23. Motzer RJ, 2007, NEW ENGL J MED, V356, P115, DOI 10.1056/NEJMoa065044
  24. Motzer RJ, 2014, J CLIN ONCOL, V32, P2766, DOI 10.1200/JCO.2013.54.6911
  25. Motzer RJ, 2013, NEW ENGL J MED, V369, P722, DOI 10.1056/NEJMoa1303989
  26. Network. NCC, 2019, KIDN CANC VERS 4 201
  27. Rini B, 2018, ESMO ANN M GEN CANC, V20
  28. Sternberg CN, 2010, J CLIN ONCOL, V28, P1061, DOI 10.1200/JCO.2009.23.9764
  29. Tannir NM, 2016, EUR UROL, V69, P866, DOI 10.1016/j.eururo.2015.10.049
  30. Tsimafeyeu I, 2017, UROL ONCOL-SEMIN ORI, V35, P5, DOI 10.1016/j.urolonc.2016.07.011
  31. Zisman A, 2002, J UROLOGY, V168, P950, DOI 10.1016/S0022-5347(05)64549-1

Coleções
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - HC/InRad
Artigos e Materiais de Revistas Científicas - LIM/24
Artigos e Materiais de Revistas Científicas - ODS/03